Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Becton Dickinson (BDX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$276.71 | $315.00 | $240.00 | 16.61% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Becton Dickinson comes to $276.71. The forecasts range from a low of $240.00 to a high of $315.00. The average price target represents an increase of 16.61% from the last closing price of $237.30.
Analyst Price Targets (14)
Broker Rating
Becton Dickinson currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 6.25% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 6.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.44 | 1.44 | 1.44 | 1.44 | 1.47 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/24/2024 | Piper Sandler | Jason Bednar | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Hold | Hold |
7/2/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Strong Buy |
5/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/3/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
5/3/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Hold | Hold |
11/9/2023 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 16 |
Average Target Price | $276.71 |
LT Growth Rate | 8.80% |
Industry | Medical - Dental Supplies |
Industry Rank by ABR | 101 of 252 |
Current Quarter EPS Est: | 3.31 |